CERALIFIMOD

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H33NO4
Molecular Weight	435.5552
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC1=CC=C(COC2=CC3=C(C=C2)C(C)=C(CN4CC(C4)C(O)=O)CC3)C(OC)=C1

InChI

InChIKey=QDDQIPUKAXBMBX-UHFFFAOYSA-N

InChI=1S/C27H33NO4/c1-4-5-19-6-7-22(26(12-19)31-3)17-32-24-10-11-25-18(2)21(9-8-20(25)13-24)14-28-15-23(16-28)27(29)30/h6-7,10-13,23H,4-5,8-9,14-17H2,1-3H3,(H,29,30)

HIDE SMILES / InChI

Molecular Formula	C27H33NO4
Molecular Weight	435.5552
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26239599 | http://adisinsight.springer.com/drugs/800028369 | http://www.msdiscovery.org/research-resources/drug-pipeline/500-ono-4641

Ceralifimod (ONO-4641) is an oral, selective Sphingosine 1-phosphate receptor 1 and 5 agonist. It was studied in the phase 2 trials for the treatment of multiple sclerosis, however, further, development was discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sphingosine 1-phosphate receptor Edg-1 12 Target ID: CHEMBL4333 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26239599	Agonist 2678
Sphingosine 1-phosphate receptor Edg-8 9 Target ID: CHEMBL2274 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26239599	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Multiple sclerosis 104 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26239599	Primary		Phase II 1132	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
985 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
111 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.01 mg single, oral dose: 0.01 mg route of administration: Oral experiment type: SINGLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1166 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.025 mg 1 times / day multiple, oral dose: 0.025 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2260 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.05 mg 1 times / day multiple, oral dose: 0.05 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
262 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.025 mg single, oral dose: 0.025 mg route of administration: Oral experiment type: SINGLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
434 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.01 mg 1 times / day multiple, oral dose: 0.01 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4428 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.1 mg 1 times / day multiple, oral dose: 0.1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
507 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.05 mg single, oral dose: 0.05 mg route of administration: Oral experiment type: SINGLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
18620 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1967 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.01 mg single, oral dose: 0.01 mg route of administration: Oral experiment type: SINGLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
24527 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.025 mg 1 times / day multiple, oral dose: 0.025 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
48497 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.05 mg 1 times / day multiple, oral dose: 0.05 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4908 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.025 mg single, oral dose: 0.025 mg route of administration: Oral experiment type: SINGLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9219 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.01 mg 1 times / day multiple, oral dose: 0.01 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
93517 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.1 mg 1 times / day multiple, oral dose: 0.1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9530 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.05 mg single, oral dose: 0.05 mg route of administration: Oral experiment type: SINGLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
81.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.025 mg 1 times / day multiple, oral dose: 0.025 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
89 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.05 mg 1 times / day multiple, oral dose: 0.05 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
81.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.01 mg 1 times / day multiple, oral dose: 0.01 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
84.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155	0.1 mg 1 times / day multiple, oral dose: 0.1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CERALIFIMOD plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00IG25	https://www.1pchem.com/search?query=1P00IG25
AChemBlock	M15718	http://www.achemblock.com/catalogsearch/result/?q=M15718
Angene	AGN-PC-0WCXOA	http://www.angenechemical.com/productshow/AGN-PC-0WCXOA.html
AstaTech	42501	http://astatechinc.com/CPSResult.php?CRNO=42501
BLD Pharm	BD303532	http://www.bldpharm.com/search/Search.html?keyword=BD303532
ChemShuttle	169846	https://www.chemshuttle.com/catalogsearch/result/?q=169846
Combi-Blocks	QV-2468	http://www.combi-blocks.com/cgi-bin/find.cgi?QV-2468
KeyOrganics	AS-35225	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-35225
MolPort	MolPort-039-137-320	https://www.molport.com/shop/molecule-link/MolPort-039-137-320
Molnova	M16432	https://www.molnova.com/en/serch-list.html?keywords=M16432
MuseChem	I005960	https://www.musechem.com/product/I005960.html
ShangHai Biochempartner	BCP20384	http://www.biochempartner.com/search_BCP20384
eMolecules	60174464	https://orderbb.emolecules.com/search/#?query=60174464
mcule	MCULE-5086908792	https://mcule.com/MCULE-5086908792/

PubMed

Title	Date	PubMed
		201081782
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.	2010 Oct	20623701
Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis.	2013 Jan	23199323
Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm.	2015 Sep	25855155

Patents

Sample Use Guides

In Vivo Use Guide

The phase 2 DreaMS trial: patients with relapsing-remitting multiple sclerosis were randomized to 0.05 mg, 0.1 mg, or 0.15 mg of Ceralifimod (ONO-4641), or placebo.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:11:57 GMT 2023` Edited by `admin` on `Sat Dec 16 08:11:57 GMT 2023`
Record UNII	BZ2O8A84A4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CERALIFIMOD

Official Name

English

ceralifimod [INN]

Common Name

English

Ceralifimod [WHO-DD]

Common Name

English

1-((6-((2-METHOXY-4-PROPYLBENZYL)OXY)-1-METHYL-3,4-DIHYDRO-2-NAPHTHALENYL)METHYL)AZETIDINE-3-CARBOXYLIC ACID

Systematic Name

English

1-((6-((2-METHOXY-4-PROPYLPHENYL)METHOXY)-1-METHYL-3,4-DIHYDRONAPHTHALEN-2-YL(METHYL)AZETIDINE-3-CARBOXYLIC ACID

Common Name

English

Code System Code Type Description

CAS

891859-12-4